U.S. markets closed
  • S&P 500

    4,655.27
    +60.65 (+1.32%)
     
  • Dow 30

    35,135.94
    +236.60 (+0.68%)
     
  • Nasdaq

    15,782.83
    +291.18 (+1.88%)
     
  • Russell 2000

    2,241.98
    -3.96 (-0.18%)
     
  • Crude Oil

    69.90
    +1.75 (+2.57%)
     
  • Gold

    1,786.50
    -1.60 (-0.09%)
     
  • Silver

    22.94
    -0.19 (-0.84%)
     
  • EUR/USD

    1.1293
    -0.0027 (-0.24%)
     
  • 10-Yr Bond

    1.5300
    +0.0480 (+3.24%)
     
  • GBP/USD

    1.3312
    -0.0027 (-0.20%)
     
  • USD/JPY

    113.5440
    +0.2340 (+0.21%)
     
  • BTC-USD

    58,228.66
    +2,389.12 (+4.28%)
     
  • CMC Crypto 200

    1,461.03
    +32.10 (+2.25%)
     
  • FTSE 100

    7,109.95
    +65.92 (+0.94%)
     
  • Nikkei 225

    28,283.92
    -467.70 (-1.63%)
     

Idexx Laboratories (IDXX) Stock Sinks As Market Gains: What You Should Know

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Idexx Laboratories (IDXX) closed at $651.96 in the latest trading session, marking a -0.09% move from the prior day. This change lagged the S&P 500's 0.18% gain on the day.

Prior to today's trading, shares of the Animal diagnostic and health care company had gained 0.38% over the past month. This has outpaced the Medical sector's loss of 1.77% and lagged the S&P 500's gain of 2.96% in that time.

IDXX will be looking to display strength as it nears its next earnings release, which is expected to be November 2, 2021. On that day, IDXX is projected to report earnings of $1.88 per share, which would represent year-over-year growth of 11.24%. Meanwhile, our latest consensus estimate is calling for revenue of $793.26 million, up 9.9% from the prior-year quarter.

Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $8.36 per share and revenue of $3.19 billion. These totals would mark changes of +24.59% and +17.91%, respectively, from last year.

Any recent changes to analyst estimates for IDXX should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 0.14% higher. IDXX is currently a Zacks Rank #3 (Hold).

Looking at its valuation, IDXX is holding a Forward P/E ratio of 78.01. This represents a premium compared to its industry's average Forward P/E of 51.24.

Also, we should mention that IDXX has a PEG ratio of 3.92. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Instruments was holding an average PEG ratio of 3.3 at yesterday's closing price.

The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 158, putting it in the bottom 38% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
IDEXX Laboratories, Inc. (IDXX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research